Clinical Guidelines

Insulin Glargine (Lantus ®) and a Possible Link with Cancer (October 2017)

Home » Clinical Guidelines » Insulin Glargine (Lantus ®) and a Possible Link with Cancer (October 2017)

Date: October 2017 | Category: Type 1 Diabetes Mellitus | Type 2 Diabetes Mellitus |

Position Statement
Download the full version of the ‘ADS Position Statement on Insulin Glargine (Lantus®) and a Possible Link with Cancer – PDF (Posted: October, 2017)

Other Resources

Australian Diabetes Society

For all enquiries:

145 Macquarie Street,
Sydney, NSW, 2000

p: 61 2 9169 3859
e: admin@diabetessociety.com.au

Divisions

Acknowledgement of Country
The Australian Diabetes Society acknowledges the Traditional Custodians of the lands upon which we live, learn and work.
We pay our respects to Elders both past, present and future.

Design by Aptly

Clinical Guidelines

Insulin Glargine (Lantus ®) and a Possible Link with Cancer (October 2017)

Categories

Other Resources

Australian Diabetes Society

Divisions